Beli Lucius Niraparib secara online

IDR 2,999,993

1,600+ terjual
Harga Promo

Apotek fisik Hong Kong dengan jaminan produk asli 100%

Keunggulan Produk

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Jaminan Layanan

Pengiriman Lintas NegaraApotek ResmiDitinjau ApotekerJaminan Keaslian

Spesifikasi

Spesifikasi
100mg*30 tablets
Produsen
Lucius Pharmaceuticals
Pengiriman
Hong Kong

Stok 10000

Informasi Produk

Nama Inggris
Niraparib
Nama Generik
Niraparib

Spesifikasi

Spesifikasi
100mg*30 tablets
Produsen
Lucius Pharmaceuticals
Pengiriman
Hong Kong

Rincian Lengkap

Indikasi

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mekanisme Kerja

PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,

Farmakologi

12.1 Mekanisme Kerja PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,

Dosis dan Penggunaan

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA , BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg , 5 mg , BRCA BRCAm mCRPC AKEEGA 200 /1,

Peringatan

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE , AKEEGA ,MDS AML 0.6% (2/347) 0.5% (1/212), AKEEGA MDS/ AML , / DNA MDS/AML , MDS/AML, AKEEGA

Interaksi Obat

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)], 7.2 AKEEGA CYP2D6 , CYP2D6 ,

Efek Samping

/ [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] [ Peringatan(5.4)] [ Peringatan(5.5)] [ Peringatan(5.6)] 223 [ Peringatan(5.7)] [ Peringatan(5.8)] 6.1

Penyimpanan

AKEEGA® AKEEGA 50 /500 , , , “N 50 A”, 60 NDC 57894-050-60 AKEEGA 100 /500 , , , “N 50 A”,

Package Insert

Ingredients

11 AKEEGA® ADP- PARP 2-{4-[(3S)- -3- ] }-2H- 7- 4- 1:1:1 C₂₆H₃₀N₄O₅S, 510.61 g/mol

Indications

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Dosis dan Penggunaan

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA , BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg , 5 mg , BRCA BRCAm mCRPC AKEEGA 200 /1,

Efek Samping

/ [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] [ Peringatan(5.4)] [ Peringatan(5.5)] [ Peringatan(5.6)] 223 [ Peringatan(5.7)] [ Peringatan(5.8)] 6.1

Precautions

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE , AKEEGA ,MDS AML 0.6% (2/347) 0.5% (1/212), AKEEGA MDS/ AML , / DNA MDS/AML , MDS/AML, AKEEGA

Use in Pregnancy and Lactation

8.1 AKEEGA Mekanisme Kerja[ (12.1)],AKEEGA AKEEGA / - , , [ Peringatan (5.2) (13.1)] Mekanisme Kerja ,

Interaksi Obat

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)], 7.2 AKEEGA CYP2D6 , CYP2D6 ,

Clinical Pharmacology

12 12.1 Mekanisme Kerja PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 , , , 17α- /C17,20-

Clinical Studies

14 14.1 BRCA2 (mCSPC) AKEEGA AMPLITUDE (NCT04497844) , 696 (HRR) (HRRm) mCSPC , 1:1 , 200 mg 1000 mg (n=348) (n=348) 5 mg, 14 (ADT) mCSPC , 45 6 6 ADT HRR BRCA2 CDK12

Penyimpanan

AKEEGA® AKEEGA 50 /500 , , , “N 50 A”, 60 NDC 57894-050-60 AKEEGA 100 /500 , , , “N 50 A”,

Ulasan Produk (17)

Filter: All Reviews
4.8★★★★★
+o***e· 3 weeks ago
★★★★
+t***3· 1 months ago
Pembelian Terverifikasi
★★★★★

Deskripsi produk

Indikasi

Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.

Mekanisme Kerja

PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,

Farmakologi

12.1 Mekanisme Kerja PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,

Dosis dan Penggunaan

2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA , BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg , 5 mg , BRCA BRCAm mCRPC AKEEGA 200 /1,

Peringatan

5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE , AKEEGA ,MDS AML 0.6% (2/347) 0.5% (1/212), AKEEGA MDS/ AML , / DNA MDS/AML , MDS/AML, AKEEGA

Interaksi Obat

7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)], 7.2 AKEEGA CYP2D6 , CYP2D6 ,

Efek Samping

/ [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] [ Peringatan(5.4)] [ Peringatan(5.5)] [ Peringatan(5.6)] 223 [ Peringatan(5.7)] [ Peringatan(5.8)] 6.1

Penyimpanan

AKEEGA® AKEEGA 50 /500 , , , “N 50 A”, 60 NDC 57894-050-60 AKEEGA 100 /500 , , , “N 50 A”,